Where a treatment for DM carries a risk of hypoglycaemia (such as SUs and insulin use), the addition of an SGLT-2 inhibitor may potentiate that risk, particularly if baseline glycaemic control is reasonable at the time of initiation of treatment. This evidence concerns the gene SLC5A2 and diabetes mellitus.